Ernexa Therapeutics Plans 1-for-25 Reverse Stock Split to Meet Nasdaq’s $1.00 Rule
ERNA•Ernexa Therapeutics will implement a 1-for-25 reverse stock split effective May 4, 2026, resulting in approximately 1,166,177 shares outstanding from 29,154,431 pre-split shares. The move restores compliance with Nasdaq’s $1.00 minimum bid requirement and applies proportionate adjustments to equity awards and warrants.
1. Reverse Split Mechanics
Ernexa will combine every 25 shares of its common stock into one new share effective May 4, 2026 at 12:01 a.m. Eastern Time, reducing the share count from 29,154,431 to approximately 1,166,177 outstanding shares on a split-adjusted basis.
2. Nasdaq Listing Compliance
The reverse stock split is designed to restore compliance with Nasdaq Listing Rule 5550(a)(2)’s $1.00 minimum bid price requirement, ensuring the company’s continued listing on the Nasdaq Capital Market under the existing trading symbol.
3. Equity Awards and Warrants Adjustments
Outstanding warrants (trading under ERNAW) and equity incentive awards will receive proportional adjustments to both exercise prices and share counts, with no change to warrant CUSIPs and all post-split shares remaining fully paid and non-assessable.
